Orange County Business Journal

Questcor Tumbles on News of Government Probe

Vita Reed Monday, September 24, 2012

Anaheim-based Questcor Pharmaceuticals Inc.’s shares dropped today after it disclosed in a federal filing that it “became aware of a U.S. government investigation” involving its promotional practices for its sole drug.

The drug maker’s shares were down 33% in midday trading to a market value of $1.2 billion.

Questcor makes H.P. Acthar Gel, an injectable medication primarily sold for treating kidney disease nephrotic syndrome and for multiple sclerosis flare-ups. Acthar is approved for 19 different indications in total.

The company’s stock went on a roller-coaster ride last week after a short seller disclosed that insurer Aetna Inc. was going to limit coverage of Acthar to treatment of infantile spasms, a rare form of epilepsy.

That sent shares down 48% on Sept. 19. They rebounded partially the next day when company officials said that it didn’t expect Aetna’s decision to hurt its business and that it was in discussions with the insurer.

Facebook Twitter Linked-In